Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Ipilimumab in Early Breast Cancer (BELLINI)
NCT03815890Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2019
- Primary completion
- Jan 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in breast cancer (5 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Pathological Complete Response Rate. Started Oct 2019; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03815890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815890.